Nature Communications (Oct 2017)
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
- Jiqiu Cheng,
- Jonas Demeulemeester,
- David C. Wedge,
- Hans Kristian M. Vollan,
- Jason J. Pitt,
- Hege G. Russnes,
- Bina P. Pandey,
- Gro Nilsen,
- Silje Nord,
- Graham R. Bignell,
- Kevin P. White,
- Anne-Lise Børresen-Dale,
- Peter J. Campbell,
- Vessela N. Kristensen,
- Michael R. Stratton,
- Ole Christian Lingjærde,
- Yves Moreau,
- Peter Van Loo
Affiliations
- Jiqiu Cheng
- Department of Electrical Engineering (ESAT) and iMinds Future Health Department, University of Leuven
- Jonas Demeulemeester
- The Francis Crick Institute
- David C. Wedge
- Wellcome Trust Sanger Institute
- Hans Kristian M. Vollan
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet
- Jason J. Pitt
- Institute for Genomics and Systems Biology, University of Chicago
- Hege G. Russnes
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet
- Bina P. Pandey
- Department of Electrical Engineering (ESAT) and iMinds Future Health Department, University of Leuven
- Gro Nilsen
- Department of Informatics and Centre for Cancer Biomedicine, University of Oslo
- Silje Nord
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet
- Graham R. Bignell
- Wellcome Trust Sanger Institute
- Kevin P. White
- Institute for Genomics and Systems Biology, University of Chicago
- Anne-Lise Børresen-Dale
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet
- Peter J. Campbell
- Wellcome Trust Sanger Institute
- Vessela N. Kristensen
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet
- Michael R. Stratton
- Wellcome Trust Sanger Institute
- Ole Christian Lingjærde
- Department of Informatics and Centre for Cancer Biomedicine, University of Oslo
- Yves Moreau
- Department of Electrical Engineering (ESAT) and iMinds Future Health Department, University of Leuven
- Peter Van Loo
- The Francis Crick Institute
- DOI
- https://doi.org/10.1038/s41467-017-01355-0
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Homozygous deletions are rare in cancers and often target tumour suppressor genes. Here, the authors conduct pan-cancer analyses and apply statistical modelling to identify 27 candidate tumour suppressors, including MAFTRR, KIAA1551, and IGF2BP2.
